A detailed history of Vanguard Group Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,760,619 shares of ALDX stock, worth $17.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,760,619
Previous 3,742,386 0.49%
Holding current value
$17.9 Million
Previous $12.4 Million 63.63%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.19 - $6.32 $58,163 - $115,232
18,233 Added 0.49%
3,760,619 $20.3 Million
Q2 2024

Aug 13, 2024

SELL
$3.25 - $4.72 $411,752 - $597,990
-126,693 Reduced 3.27%
3,742,386 $12.4 Million
Q1 2024

May 10, 2024

SELL
$2.77 - $4.22 $162,094 - $246,945
-58,518 Reduced 1.49%
3,869,079 $12.7 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $6.06 $1.09 Million - $4.49 Million
740,177 Added 23.22%
3,927,597 $13.8 Million
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $44,150 - $58,964
7,226 Added 0.23%
3,187,420 $21.3 Million
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $4.84 Million - $8.1 Million
681,033 Added 27.25%
3,180,194 $26.7 Million
Q1 2023

May 15, 2023

BUY
$5.77 - $9.93 $39,766 - $68,437
6,892 Added 0.28%
2,499,161 $24.8 Million
Q4 2022

Feb 10, 2023

SELL
$5.08 - $7.09 $119,964 - $167,430
-23,615 Reduced 0.94%
2,492,269 $17.3 Million
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $300,678 - $612,435
79,126 Added 3.25%
2,515,884 $13.4 Million
Q2 2022

Aug 12, 2022

SELL
$2.43 - $4.85 $1.28 Million - $2.55 Million
-524,877 Reduced 17.72%
2,436,758 $9.72 Million
Q1 2022

May 13, 2022

BUY
$3.25 - $5.17 $480,060 - $763,665
147,711 Added 5.25%
2,961,635 $13.2 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $302,848 - $833,264
86,528 Added 3.17%
2,813,924 $11.3 Million
Q3 2021

Nov 12, 2021

BUY
$7.94 - $11.31 $245,711 - $349,999
30,946 Added 1.15%
2,727,396 $23.9 Million
Q2 2021

Aug 13, 2021

BUY
$10.44 - $14.85 $28.2 Million - $40 Million
2,696,450 New
2,696,450 $30.6 Million

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $278M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.